Free Trial

BioCryst Pharmaceuticals (BCRX) News Today

BioCryst Pharmaceuticals logo
$6.81 +0.39 (+6.07%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$6.82 +0.01 (+0.16%)
As of 10/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why Is BioCryst Pharmaceuticals Up Today?

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) — Shares are trading higher after a flurry of analyst upgrades and price-target increases, alongside BioCryst’s announced acquisition of Astria Therapeutics (navenibart). Investors are reacting to both the strategic growth case and short‑term financial/transaction risks; watch the company’s conference call and financing details.

  • Positive Sentiment: Cantor Fitzgerald raised its price target to $26 and kept an "overweight" rating — another bullish signal from sell‑side coverage. Article
  • Positive Sentiment: TD Cowen initiated coverage with a "buy" rating and $30 target, adding momentum to the bullish analyst narrative. Article
  • Positive Sentiment: Other firms (Needham to $20; JMP to $27) also lifted targets/ratings today, broadening analyst upside expectations. Needham JMP
  • Positive Sentiment: Wedbush raised Q3 and FY2025 EPS estimates and maintains an Outperform rating, supporting expectations for improved near‑term profitability. Article
  • Positive Sentiment: Strategic acquisition of Astria (navenibart) adds a Phase‑3, long‑acting injectable for HAE that could materially expand BioCryst’s product set and long‑term revenue runway; company expects accretion and continued non‑GAAP profitability. Press release
  • Neutral Sentiment: BioCryst hosted an M&A call and posted transcripts/slides — useful for diligence on deal terms, timelines (close expected Q1 2026) and clinical milestones (Phase‑3 readout early 2027). Call transcript
  • Negative Sentiment: Initial market reaction was negative: shares gapped down on the deal announcement while Astria stock jumped — investors cited dilution, near‑term financing and integration risk. Market reaction
  • Negative Sentiment: Transaction includes a debt commitment (up to $550M from Blackstone) and stock consideration — increases leverage/dilution risk that could pressure the share price if financing terms or execution disappoint. Deal details

What to watch: the investor conference call/webcast, deal close and financing details, and navenibart’s Phase‑3 ALPHA‑ORBIT readout timeframe (early 2027). These will drive whether the market rewards the strategic rationale or focuses on near‑term dilution and execution risk.

Posted 6h agoAI Generated. May Contain Errors.

BCRX Latest News

Wedbush Issues Optimistic Outlook for BCRX Earnings
BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript
BioCryst to buy Astria Therapeutics in $700 million deal
BioCryst Sells European ORLADEYO Business for $250M
BioCryst: Blue Light Special In Small Cap Biotech Aisle
Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCRX Media Mentions By Week

BCRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCRX
News Sentiment

0.59

0.72

Average
Medical
News Sentiment

BCRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCRX Articles
This Week

29

8

BCRX Articles
Average Week

Get the Latest News and Ratings for BCRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioCryst Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:BCRX) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners